v3.26.1
Shareholders’ Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Jun. 02, 2026
Jan. 31, 2026
Dec. 31, 2025
Jun. 30, 2025
Apr. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Shareholders’ Equity [Line Items]              
Voting rights           one  
Net proceeds received           $ 26,122 $ 37,431
Number of shares available for grant           13,069,670  
Unrecognized compensation costs           $ 13,949  
Weighted average period           2 years 6 months  
Number of warrant outstanding     3,237,000     3,237,000  
Proceeds from issuance of Ordinary shares, net           $ 26,122 36,756
Gross proceeds from issuance of ordinary shares           $ 26,122 36,756
Trading day volume weighted average price           30 days  
Percentage of ordinary share premium           25.00%  
Compensation expense           $ 6,700 5,331
Common Stock, Shares, Issued     88,009,737     92,332,873  
Private Placement [Member]              
Shareholders’ Equity [Line Items]              
Proceeds from issuance of private placement           $ 20,000  
Share Purchase Agreement [Member]              
Shareholders’ Equity [Line Items]              
Issuance of shares         14,110,121    
Purchase price of per share         $ 2.612    
Net proceeds received         $ 36,756    
Trading day volume weighted average price 30 days            
Common Stock, Shares, Issued 1,668,057            
Construction of Hudson NH Facility [Member]              
Shareholders’ Equity [Line Items]              
Total compensation cost         $ 100    
Number of shares issued for services       226,202      
Increase to additional paid in capital in exchange for services       $ 675      
Common stock, par value            
Oramed [Member]              
Shareholders’ Equity [Line Items]              
Total compensation cost             $ 2,780
Number of warrant to purchase       2,390,000     2,390,000
Warrants exercise price       $ 3.474     $ 3.474
Compensation expense           $ 481 $ 42
Ordinary Shares [Member]              
Shareholders’ Equity [Line Items]              
Issuance of shares           3,111,059 14,336,323
Purchase price of per share $ 11.99            
Net proceeds received          
Percentage of ordinary share premium 25.00%            
Purchase ordinary shares amount $ 5,000            
Ordinary Shares [Member] | Share Purchase Agreement [Member]              
Shareholders’ Equity [Line Items]              
Issuance of shares   1,443,002 2,255,156        
Purchase price of per share   $ 6.93 $ 3.88        
Proceeds from issuance of Ordinary shares, net   $ 10,000 $ 8,740        
Common stock, par value            
Gross proceeds from issuance of ordinary shares   $ 10,000 $ 8,740        
Ordinary Shares [Member] | Oramed [Member]              
Shareholders’ Equity [Line Items]              
Warrants exercise price       $ 3.9     $ 3.9
Number of warrant outstanding       847,000     847,000
2021 Share Incentive Plan [Member]              
Shareholders’ Equity [Line Items]              
Number of shares available for grant           27,315,022  
Vesting period           4 years  
Expiry period           10 years